Portuguese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

pneumothorax/tyrosine

O link é salvo na área de transferência
Página 1 a partir de 21 resultados
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used in patients with EGFR-mutant lung cancer. Meanwhile, thermal ablation such as microwave ablation has been an option for selected patients. Herein, we describe three cases of pneumothorax that occurred in
OBJECTIVE Research biopsies (RBs) are crucial for developing novel molecular targeted agents. However, the safety and diagnostic yields of RBs have not been investigated in EGFR mutation-positive non-small cell lung cancer (NSCLC) patients pretreated with epidermal growth factor receptor (EGFR)

Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study.

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
BACKGROUND The tyrosine kinase inhibitor pazopanib is used for treatment of sarcoma. Recent studies have suggested that the use of pazopanib may lead to the development of pneumothorax, an unexpected adverse effect in patients with sarcoma metastatic to the chest. METHODS We conducted a
Pazopanib, a multitargeting tyrosine kinase inhibitor, has single-agent activity in patients with advanced soft-tissue sarcoma. Herein, we describe 2 cases of pneumothorax that occurred during pazopanib treatment in patients with soft-tissue sarcoma. These 2 patients had multiple lung metastases.

A Case Report of Secondary Simultaneous Bilateral Pneumothorax Due to Pazopanib Treatment.

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Secondary spontaneous pneumothorax almost always develops secondary to an underlying lung disease. A pneumothorax secondary to a malignancy is very rare, and is observed most frequently in soft tissue sarcomas. Pazopanib, a tyrosine kinase inhibitor, is used in metastatic soft tissue sarcomas
Apatinib, a specific tyrosine kinase inhibitor (TKI) that targets mainly vascular endothelial growth factor receptor-2 (VEGFR-2) as well as Ret, c-Kit and c-Src, has been assessed in patients with advanced osteosarcoma (phase II), the primary report of which has been published in PMID

Bilateral spontaneous pneumothoraces in anaplastic thyroid cancer.

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Spontaneous pneumothorax is rarely associated with cancer. We describe a 73 year old man who presented with recurrent tumor in the right neck, mediastinal lymphadenopathy and bilateral pulmonary nodules after thyroidectomy. He was treated with lenvatinib and presented with bilateral pneumothoraces.
BACKGROUND The efficacy of nintedanib, a multitarget receptor tyrosine kinase inhibitor, has been demonstrated in recent randomized controlled trials involving patients with idiopathic pulmonary fibrosis (IPF). However, accelerated disease progression after nintedanib discontinuation has never been

Atypical response to erlotinib in a patient with metastatic lung adenocarcinoma: a case report.

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
BACKGROUND Tyrosine kinase inhibitors are widely prescribed in thoracic oncology and have excellent responses as a first-line treatment for locally advanced or metastatic lung cancer with epidermal growth factor receptor mutations. The side effects of tyrosine kinase inhibitors are mostly

[Interstitial lung disease].

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
This concise article summarizes recent advances in the field of interstitial lung disease (ILD) with particular focus on clinically relevant findings. As a novel treatment option for idiopathic pulmonary fibrosis (IPF), pirfenidone has been granted marketing authorization in the European Union for
A 56-year-old man was referred to our clinic because of left lumbar pain and a left solitary renal tumor (9. 8 cm in diameter) and bilateral pulmonary metastases detected by computed tomographic scan. Pathologic diagnosis following open radical nephrectomy was papillary renal cell carcinoma, G2,

Pazopanib and soft-tissue sarcomas. Too toxic.

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Soft-tissue sarcomas are rare tumours of mesenchymal origin. Patients with metastatic disease have a median survival of about 10 months. Doxorubicin, an anthracycline, is often used to reduce tumour volume, but it does not prolong overall survival. Pazopanib, a multiple tyrosine kinase inhibitor
Antiangiogenesis tyrosine kinase inhibitors (TKIs) have been shown to prolong progression-free survival (PFS) in advanced osteosarcoma. Methylsulfonic apatinib is a TKI that specifically inhibits vascular endothelial growth factor receptor-2. We aim to assess apatinib in patients with

Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China.

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising effects on prolonging progression-free survival (PFS) for advanced sarcoma after failure of standard multimodal Therapy. Methylsulfonic apatinib is one of those TKIs which specifically inhibits VEGFR-2. This paper

Feasibility of re-biopsy and EGFR mutation analysis in patients with non-small cell lung cancer.

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
BACKGROUND In cases of EGFR-tyrosine kinase inhibitor (TKI) failure, re-biopsy may be useful to understand resistance mechanisms and guide further treatment decisions. However, performing re-biopsy is challenging because of several hurdles. We assessed the feasibility of re-biopsy in advanced
Junte-se à nossa
página do facebook

O mais completo banco de dados de ervas medicinais apoiado pela ciência

  • Funciona em 55 idiomas
  • Curas herbais apoiadas pela ciência
  • Reconhecimento de ervas por imagem
  • Mapa GPS interativo - marcar ervas no local (em breve)
  • Leia publicações científicas relacionadas à sua pesquisa
  • Pesquise ervas medicinais por seus efeitos
  • Organize seus interesses e mantenha-se atualizado com as notícias de pesquisa, testes clínicos e patentes

Digite um sintoma ou doença e leia sobre ervas que podem ajudar, digite uma erva e veja as doenças e sintomas contra os quais ela é usada.
* Todas as informações são baseadas em pesquisas científicas publicadas

Google Play badgeApp Store badge